Anxiety Disorder and Depression Treatment Market To Reach USD 18.90 Billion By 2026 | Reports And Data

New York, New York, UNITED STATES

The rise in the graying population and minimal side effects associated with the treatment are some of the factors boosting the market for Anxiety Disorder and Depression Treatment.

Market Size – USD 15.60 Billion in 2018, Market Growth - CAGR of 2.4%, Market Trends – Increase in awareness regarding mental health.

NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- The Global Anxiety Disorder and Depression Treatment Market is forecast to reach USD18.90 Billion by 2026, according to a new report by Reports and Data. There has been a continued rise in the rate of depression and anxiety in the global healthcare scenario. Such a rise in the incidence rate of depression and anxiety has resulted in focusing on the global healthcare scenario and reducing the incidence rate of such a mental healthcare condition. In the year 2018, more than 300 million individuals of all ages were suffering from depression in the global scenario. There have been 800,000 incidents of suicides in the same year, the reasons behind which have been primarily depression and anxiety disorders. Such a rise in the incidence rate of depression and anxiety is one of the major factors driving the global Anxiety Disorder and Depression Treatment Market.

Request free sample of this research report at:

Globally, incidences of depression and mental health are continuously increasing in the elderly population. This population is prone to mental health issues like dementia, phobia and anxiety disorders. Hence, the increase in the graying population is also contributing to the rising demand for antidepressants and therapies to treat the mental health condition during the forecast period.

In the year 2018, the global Anxiety Disorder and Depression Treatment Market was dominated by North America. This region can be forecasted to continue this domination throughout the forecast period. The reason North America dominates the market is mainly because of the rising incidence rate of anxiety disorders and depression in a particular region. Other mentionable reasons for North America to dominate the market are supportive government policies and a higher rate of awareness, which also contribute to the growth of the market in this region. The Asia Pacific region also shows a significant presence in the global Anxiety Disorder and Depression Treatment Market and is forecasted to follow North America in terms of the market share. High prevalence of psychiatric disorders in the APAC region is one of the significant reasons for market growth in this region.

Further key findings from the report suggest

  • The rising rate of occurrence of depression and anxiety is one of the contributing factors for the high consumption rate of anti-depressants.
  • This rise in the occurrence rate of anxiety and depression is one of the major driving factors for the global Anxiety Disorder and Depression Treatment Market, contributing to market growth.
  • In the segment Drug class, the highest market share was held by antidepressants in the year 2018, followed by antidepressants. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) dominated the markets in the year 2018 with a market share of 28%.

To identify the key trends in the industry, click on the link below:

  • Rises in the occurrence rate of anxiety and depression along with incidents of suicide and terminal depression signs across different age groups are expected to fuel up the global Anxiety Disorder and Depression Treatment Market.
  • As a result of such incidents of suicide, there has been a rise in demand for therapies. In the year 2018, Cognitive Behavior Therapy [CBT] dominated the market with a market share of 30%.
  • During the forecast period, CBT is forecasted to hold a market share of 31% by 2026.
  • Key participants include Johnson & Johnson, Inc., Pfizer, GlaxoSmithKline plc., Lundbeck A/S, Inc., Sanofi- Aventis, Merck & Company, AstraZeneca PLC., Forest Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company among others.

Segments covered in the report:

For the purpose of this report, Reports and Data have segmented the global Anxiety Disorder and Depression Treatment Market based on Drug class, Therapies, Devices, Application, End-users, and Region:                      

Drug class Outlook (Revenue, USD Billion; 2016-2026)

  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Antidepressant Drugs
  • Tricyclic Antidepressants (TCAs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Benzodiazepines
  • Atypical Antipsychotics
  • Anticonvulsants
  • Beta-Blockers
  • Others

Therapies Outlook (Revenue, USD Billion; 2016-2026)

  • Electroconvulsive Therapy (ECT)
  • Cognitive Behavior Therapy (CBT)
  • Psychotherapy
  • Deep Brain Stimulation
  • Transcranial Magnetic Stimulation (TMS)
  • Cranial electrotherapy stimulation (CES)

Devices Outlook (Revenue, USD Billion; 2016-2026)

  • Cranial electrotherapy stimulator
  • Fisher-Wallace stimulator market

Application Outlook (Revenue, USD Billion; 2016-2026)

  • Phobia
  • Major Depressive Disorder
  • Obsessive Compulsive Disorder (OCD)
  • Post-traumatic stress disorder
  • Others

End-users Outlook (Revenue, USD Billion; 2016-2026)

  • Hospitals
  • Mental healthcare centers
  • NGOs
  • Asylums

Order Now:

Regional Outlook (Revenue, USD Million; 2016-2026)

  • North America
    • U.S.
  • Europe
    • UK
    • France
  • Asia Pacific
    • China
    • India
    • Japan
  • MEA
  • Latin America
    • Brazil

Browse more reports of Pharmaceutical category at:

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web:

Direct Line: +1-800-819-3052